ArticleBMC chemistry2026
Green TLC-densitometric method for determination of cytarabine and granisetron in spiked human plasma: optimization and whiteness assessment.
Article in BMC chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytarabine (CYT) is a cornerstone in the treatment of acute myeloid leukemia (AML) and is often co-administered with granisetron (GRS) to manage chemotherapy-induced nausea and vomiting (CINV). A precise and sensitive thin-layer chromatographic (TLC) method was developed and validated for the simultaneous determination of CYT and GRS in spiked human plasma samples. Chromatographic separation was achieved by using a developing system consisting of ethyl acetate, ethanol, and ammonia (3:6.8:0.2, by volume), and detection was performed at 240 nm. The method exhibited linearity over the concentration ranges of 0.5-3.0 µg/band for the pure samples and 0.5-3.3 µg/band in spiked plasma for the analytes. The proposed method was validated in accordance with the guidelines of the U.S. Food and Drug Administration (FDA). Its environmental sustainability was evaluated using the Modified Green Analytical Procedure Index, Analytical Greenness Calculator, and Multicolor Assessment Index, demonstrating strong performance with minor areas for improvement. Notably, this study presents the first green TLC method for the simultaneous determination of CYT and GRS in spiked human plasma, offering a valuable tool for therapeutic drug monitoring during chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.